Algebris UK Ltd Makes New Investment in Thermo Fisher Scientific Inc. (NYSE:TMO)

Algebris UK Ltd bought a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the 4th quarter, HoldingsChannel reports. The institutional investor bought 1,747 shares of the medical research company’s stock, valued at approximately $878,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Generali Investments Management Co LLC purchased a new position in Thermo Fisher Scientific during the fourth quarter valued at $2,536,000. Vinva Investment Management Ltd increased its stake in Thermo Fisher Scientific by 8.2% during the 4th quarter. Vinva Investment Management Ltd now owns 19,824 shares of the medical research company’s stock worth $10,285,000 after buying an additional 1,502 shares in the last quarter. Stokes Family Office LLC purchased a new position in shares of Thermo Fisher Scientific in the fourth quarter valued at approximately $410,000. VSM Wealth Advisory LLC purchased a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth approximately $36,000. Finally, OVERSEA CHINESE BANKING Corp Ltd lifted its holdings in Thermo Fisher Scientific by 48.3% in the 4th quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 7,908 shares of the medical research company’s stock valued at $4,114,000 after purchasing an additional 2,576 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Wall Street Analyst Weigh In

TMO has been the subject of a number of recent research reports. Morgan Stanley increased their target price on shares of Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an “overweight” rating in a research report on Friday, January 31st. Royal Bank of Canada set a $693.00 price objective on shares of Thermo Fisher Scientific in a report on Friday, January 31st. StockNews.com upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Tuesday, January 14th. Raymond James reiterated an “outperform” rating and set a $667.00 price objective (up previously from $650.00) on shares of Thermo Fisher Scientific in a research report on Monday, February 3rd. Finally, Bank of America dropped their target price on Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating for the company in a report on Friday, December 13th. Four equities research analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $653.23.

Thermo Fisher Scientific Trading Up 0.4 %

TMO opened at $521.42 on Wednesday. Thermo Fisher Scientific Inc. has a 52 week low of $493.30 and a 52 week high of $627.88. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. The business has a fifty day simple moving average of $547.72 and a 200-day simple moving average of $557.48. The firm has a market cap of $196.71 billion, a P/E ratio of 31.54, a P/E/G ratio of 2.99 and a beta of 0.79.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, beating the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. On average, equities analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th will be paid a $0.43 dividend. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. The ex-dividend date is Friday, March 14th. This represents a $1.72 annualized dividend and a dividend yield of 0.33%. Thermo Fisher Scientific’s payout ratio is 10.41%.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total transaction of $5,166,700.00. Following the sale, the chief executive officer now owns 115,174 shares in the company, valued at $59,506,950.58. This represents a 7.99 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Stephen Williamson sold 9,825 shares of the business’s stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total value of $5,753,421.75. Following the transaction, the chief financial officer now directly owns 27,296 shares of the company’s stock, valued at approximately $15,984,264.64. This represents a 26.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 23,900 shares of company stock valued at $13,106,062. 0.34% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.